Advertisement
The US subsidiary Lupin Pharmaceuticals Inc is voluntarily recalling the batches of popular antihypertensive medicines Irbesartan Tablets and Irbesartan and Hydrochlorothiazide Tablets to the consumer level in the due to the potential presence of the carcinogen N-nitrosoirbesartan.
This move comes after Lupin's ongoing assessment, which revealed that certain tested active pharmaceutical ingredient (API) batches (but not finished product batches) were above the specification limit for the impurity, N-nitrosoirbesartan.
For more details, check out the full story on the link below:
Potential Presence Of Carcinogen: Lupin Recalls Irbesartan, Irbesartan & Hydrochlorothiazide Tablets
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.